logo
welcome
Reuters

Reuters

Health

Health

Bristol Myers forecasts 2025 revenue below estimates after strong quarter

Reuters
Summary
Nutrition label

80% Informative

Shares of the drugmaker fell nearly 4% to $ 57.33 before the bell.

The company forecast 2025 revenue of around $45.5 billion , down from $48.3 billion in 2024 .

Bristol has already been contending with sharp revenue loss from its cancer drug Revlimid , which brought in nearly $13 billion in 2021 .

VR Score

92

Informative language

98

Neutral language

71

Article tone

formal

Language

English

Language complexity

36

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links